Login / Signup

Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.

Jalal DahhamRana G RizkIngrid E H KremerSilvia M A A EversMickaël J C Hiligsmann
Published in: PharmacoEconomics (2021)
MS places a huge economic burden on healthcare systems and societies in LMICs. Methodological differences and substantial variations in terms of absolute costs were found between studies, which made comparison of studies challenging. However, the cost ratios across different levels of MS severity were similar, making comparisons between studies by disease severity feasible. Cost drivers were mainly DMTs and relapse treatments, and this was consistent across studies. Yet, the distribution of cost components varied with disease severity.
Keyphrases
  • multiple sclerosis
  • healthcare
  • case control
  • mass spectrometry
  • ms ms